Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. - Wikidata - awgldk - TriplyDB

Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.

Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.

http://www.wikidata.org/entity/Q37448226

about

Suspected non-Alzheimer disease pathophysiology--concept and controversy Role of HIV in amyloid metabolism The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration.Amyloid burden and neural function in people at risk for Alzheimer's Disease.18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.Positive affect predicts cerebral glucose metabolism in late middle-aged adults.Association of hypometabolism and amyloid levels in aging, normal subjects Early detection of Alzheimer's disease using PiB and FDG PET Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects.The evolution of preclinical Alzheimer's disease: implications for prevention trials.Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease Emerging β-amyloid pathology and accelerated cortical atrophy.Mapping the Relationship of Contributing Factors for Preclinical Alzheimer's Disease.BACE1 activity impairs neuronal glucose oxidation: rescue by beta-hydroxybutyrate and lipoic acid.Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease Is amyloid-β harmful to the brain? Insights from human imaging studies Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity Cerebral amyloid PET imaging in Alzheimer's disease.Biomarker modeling of Alzheimer's disease.Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults.Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers.Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum.Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease.Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease.Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals.NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Low Cerebrospinal Fluid Aβ42 and Aβ40 are Related to White Matter Lesions in Cognitively Normal Elderly."Exceptional brain aging" without Alzheimer's disease: triggers, accelerators, and the net sum game.

P2860

Q26771270-1C0D44EE-8977-4353-9930-6B41D3CD0843 Q26824179-566917BD-75AB-4CC4-9811-7DB55D5C2285 Q26830467-B9437D2B-0615-4CE1-8E1A-D215F533C7AD Q26864063-386A81E4-22A8-43AE-B1E4-08A55733BAE8 Q33581412-D30E980A-2F3B-4E9A-8458-900C3F782686 Q33599047-DA0B0372-FE26-4CC6-AB3E-CB158A963C73 Q33740879-33C40FFF-8955-4CE8-A46C-EB3AC47BD348 Q33802786-67DD9887-3D36-4575-8F12-8456CE82A1A5 Q33927230-EB2108FB-DB0F-4637-ACE1-15B9C2E6A39B Q34483878-EEE7AEA3-31BD-42DE-8B61-95E78075CECD Q34498348-D5D9CE11-DED9-47B8-82E2-9F673070A943 Q34849048-0B04D3A9-38CB-4CAD-A9B8-18F5BCD4522E Q34940642-A29FEB5F-5E64-4ED3-9920-24EFCD179BEE Q35195654-D7DB868D-56B0-4FFE-AAA6-DFAB5AA806F4 Q35542164-1DE5B283-101C-44DC-8B68-A89C2618CC82 Q35865377-1E923F25-A795-4598-AF79-87704C817874 Q36109558-106CD549-B8E4-43B7-9F7B-403DAC93192C Q36528669-89758B28-ED63-4FAF-BEAD-9936551E47FA Q36667836-2D8DEF5E-DCD9-4B6C-A2C3-D8DE660BA567 Q36870947-025FA8D4-4B83-4D89-B276-E920A68BA1D9 Q37029599-76E3E326-9968-43C5-BDB2-12A7F4E5EAA6 Q37188315-B5488D65-8438-477F-B9BB-A384C3655721 Q37291586-2A92328E-902A-409A-BCEE-335DADEA490A Q37459083-52E041E2-E43C-499F-8C66-846E0EECC68A Q37592824-13561FCE-7742-4396-82A2-6D4744C0D187 Q37603879-10564672-6D24-4402-B8FE-26E0E639B59F Q37698159-0E8F716F-99D5-4346-AD91-0CC2E52EAE34 Q39466317-5B3AABE3-6ACD-4861-803A-7C3C2FA16BE3 Q40101067-48471B17-144C-40EC-AE9D-7F505BBF5153 Q41566620-70A95C20-7799-4BEB-96A8-C5DAC5A11367 Q41635671-2500CAD8-D1AE-4F97-8604-E4B2DF851C6C Q41654319-E0FA5210-5F82-4B19-9DF3-E11C5FE22351 Q47722152-07BB07A4-C860-4DD0-BDE5-AFB8EA4E6BE1 Q48020440-943C782A-DEED-4BCB-8792-87266C07F7F7 Q50980528-BBD56A97-E3EC-4CA6-A872-4AC09F422E40 Q52589491-9C582789-3534-43A7-9662-D5FF0CB38B51 Q55028222-82CA72B9-9237-4C72-9171-66206459E7EF Q55416628-1D833DA6-FD07-42B7-B8B7-AC3470D6BA63

P2860

Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.

http://www.wikidata.org/entity/Q37448226

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Selective worsening of brain i ...... ly persons with β-amyloidosis.

@en

Selective worsening of brain i ...... ly persons with β-amyloidosis.

@nl

type

label

Selective worsening of brain i ...... ly persons with β-amyloidosis.

@en

Selective worsening of brain i ...... ly persons with β-amyloidosis.

@nl

prefLabel

Selective worsening of brain i ...... ly persons with β-amyloidosis.

@en

Selective worsening of brain i ...... ly persons with β-amyloidosis.

@nl

P1433

Q37448226-BD2D9435-7B27-49DC-BFEE-5423D44825DA

P1476

Q37448226-A620DDEC-2597-4299-A452-47BD3953907E

P2093

Q37448226-332204CB-FA67-42A9-8BE9-1FAEAED207AE

Q37448226-3CEFAB0E-E298-4990-975E-00C5E2B5E461

Q37448226-4A504190-F66E-4DD3-8982-58A0112C4997

Q37448226-4BC416EC-A76F-41EE-B134-7FA97748C7EB

Q37448226-55F8B21F-51BA-448C-AA84-5084CABBD146

Q37448226-6FD156D8-4EE7-45C2-98AD-2C68828C72E7

Q37448226-8723B2CD-F5FB-4DE2-99A1-F8F94CF4B831

Q37448226-F186E6F1-6054-4C0D-AB78-CF0C8901AF51

Q37448226-F851927F-A0C1-4F38-BFF4-6B3D70E48E86

P2860

Q37448226-023A910A-1CD7-4CD4-85CF-16CD5286C185

Q37448226-099FA327-87CE-4D26-B82A-B6D5DC5EED29

Q37448226-195511B5-3DA2-4BB9-9E61-244A13AF919D

Q37448226-1DAD42DC-07CB-49D2-A8E9-FCDAB5BFA1EF

Q37448226-1F9E6815-AF09-4666-895D-D8B02385C60C

Q37448226-2AB35807-DEC3-454D-AB7B-E41BECEF1787

Q37448226-2C1DE310-460A-443A-87AF-BE04DADDE963

Q37448226-38174023-B867-4E78-8F7E-30F491F9D3E7

Q37448226-3B2EA9CF-7F89-49A6-AC0B-A4D8AA851C47

Q37448226-3E34EAEF-0DF5-4B3E-A6C2-B8E1499CE360

P304

Q37448226-2CC2D666-8758-4651-B2CB-E568D9C33136

P31

Q37448226-AB5EF29B-844F-48DE-855E-D2C390D0FB7D

P356

Q37448226-0CE2B128-98F0-4D95-9FD3-9082D24FA7FE

P407

Q37448226-8E65B632-2CD1-49C7-9382-10AE6FAE44D9

P433

Q37448226-A73FD3BD-D9A1-4A4B-B837-68FC20CF4E32

P478

Q37448226-061DBBD4-D633-4D67-9D9C-C9F6487CF2F7

P50

Q37448226-11C81323-77D6-4766-86FD-3DABC49881B4

Q37448226-17D02DF1-92E8-4CA7-A2AA-F9645B74923A

Q37448226-75AA1022-F14E-4756-906C-6E6AB7669BAC

Q37448226-DCD296D5-FE76-4D50-A6AD-8914EE5D37F1

P577

Q37448226-5CB96ABE-8870-4AFB-87D8-E0536857B0F3

P5875

Q37448226-C870CE6F-ACD0-4546-9D4A-9D7A7EF11A2F

P698

Q37448226-0A03CF70-316E-4502-B0D0-3677C4BDD03C

P921

Q37448226-B562DF30-775A-4EBF-8315-2C7AC4247FCE

P932

Q37448226-BF8867BA-9E73-43DF-AD9E-D6DAAB3E5481

P356

JAMANEUROL.2013.182

P1433

P1476

Selective worsening of brain i ...... ly persons with β-amyloidosis.

@en

P2093

Bradley F Boeve

http://www.w3.org/2001/XMLSchema#string

Heather J Wiste

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Gunter

http://www.w3.org/2001/XMLSchema#string

Matthew L Senjem

http://www.w3.org/2001/XMLSchema#string

Michelle M Mielke

http://www.w3.org/2001/XMLSchema#string

Prashanthi Vemuri

http://www.w3.org/2001/XMLSchema#string

Rosebud O Roberts

http://www.w3.org/2001/XMLSchema#string

Stephen D Weigand

http://www.w3.org/2001/XMLSchema#string

Val J Lowe

http://www.w3.org/2001/XMLSchema#string

P2860

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Atrophy rates accelerate in amnestic mild cognitive impairment.

Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.

P304

1030-1038

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMANEUROL.2013.182

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Ronald C. Petersen

David S Knopman

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

241697840

http://www.w3.org/2001/XMLSchema#string

P698

23797806

http://www.w3.org/2001/XMLSchema#string

P921

P932

3884555

http://www.w3.org/2001/XMLSchema#string